Herpes Zoster and COVID-19 Vaccination: A Narrative Review

References

• Sharma A, Ahmad Farouk I, Lal SK. COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention. Viruses. 2021;13(2):202. doi:10.3390/v13020202
   PubMed Web of Science ®Google Scholar
• Hadj Hassine I. Covid-19 vaccines and variants of concern: a review. Rev Med Virol. 2022;32(4):e2313. doi:10.1002/rmv.2313
   PubMed Web of Science ®Google Scholar
• Smith DRM, Chervet S, Pinettes T, et al. How have mathematical models contributed to understanding the transmission and control of SARS-CoV-2 in healthcare settings? A systematic search and review. J Hosp Infect. 2023;141:132–141. doi:10.1016/j.jhin.2023.07.028
   PubMed Web of Science ®Google Scholar
• Salian VS, Wright JA, Vedell PT, et al. COVID-19 transmission, current treatment, and future therapeutic strategies. Mol Pharm. 2021;18(3):754–771. doi:10.1021/acs.molpharmaceut.0c00608
   PubMed Web of Science ®Google Scholar
• Khan M, Adil SF, Alkhathlan HZ, et al. COVID-19: a global challenge with old history, epidemiology and progress so far. Molecules. 2020;26(1):39. doi:10.3390/molecules26010039
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Fabbrocini G, et al. The role of teledermatology during the COVID-19 pandemic: a narrative review. Clin Cosmet Investig Dermatol. 2022;15:2785–2793. doi:10.2147/CCID.S377029
   PubMed Web of Science ®Google Scholar
• Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID-19 vaccines mix-and-match: the concept, the efficacy and the doubts. J Med Virol. 2022;94(4):1294–1299. doi:10.1002/jmv.27463
   PubMed Web of Science ®Google Scholar
• Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. Public Health. 2021;194:245–251. doi:10.1016/j.puhe.2021.02.025
   PubMed Web of Science ®Google Scholar
• Joshi A, Kaur M, Kaur R, Grover A, Nash D, El-Mohandes A. Predictors of COVID-19 vaccine acceptance, intention, and hesitancy: a scoping review. Front Public Heal. 2021;9:698111. doi:10.3389/fpubh.2021.698111
   PubMed Web of Science ®Google Scholar
• Martora F, Villani A, Marasca C, Fabbrocini G, Potestio L. Skin reaction after SARS-CoV-2 vaccines Reply to “cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience”. J Eur Acad Dermatol Venereol. 2023;37(1):e43–e44. doi:10.1111/jdv.18531
   PubMed Web of Science ®Google Scholar
• Potestio L, Fabbrocini G, D’Agostino M, Piscitelli I, Martora F. Cutaneous reactions following COVID-19 vaccination: the evidence says “less fear”. J Cosmet Dermatol. 2023;22(1):28–29. doi:10.1111/jocd.15533
   PubMed Web of Science ®Google Scholar
• Potestio L, Villani A, Fabbrocini G, Martora F. Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: what we should know? J Cosmet Dermatol. 2022;21(11):5339–5340. doi:10.1111/jocd.15331
   PubMed Web of Science ®Google Scholar
• Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202–221. doi:10.1016/j.cmi.2021.10.005
   PubMed Web of Science ®Google Scholar
• De Lucia M, Potestio L, Costanzo L, Fabbrocini G, Gallo L. Scabies outbreak during COVID-19: an Italian experience. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. Dermatol Ther. 2022;35(2):e15225. doi:10.1111/dth.15225
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Villani A, Tajani A, Fabbrocini G, Potestio L. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022;21(6):2309–2310. doi:10.1111/jocd.14938
   PubMed Web of Science ®Google Scholar
• Maronese CA, Caproni M, Moltrasio C, et al. Bullous pemphigoid associated with COVID-19 vaccines: an Italian multicentre study. Front Med. 2022;9:841506. doi:10.3389/fmed.2022.841506
   Web of Science ®Google Scholar
• Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292–1293. doi:10.1002/jmv.27535
   PubMed Web of Science ®Google Scholar
• Marzano AV, Maronese CA, Genovese G, et al. Urticarial vasculitis: clinical and laboratory findings with a particular emphasis on differential diagnosis. J Allergy Clin Immunol. 2022;149(4):1137–1149. doi:10.1016/j.jaci.2022.02.007
   PubMed Web of Science ®Google Scholar
• Maronese CA, Zelin E, Avallone G, et al. Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic. Front Med. 2022;9:996288. doi:10.3389/fmed.2022.996288
   Web of Science ®Google Scholar
• Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2023;22(1):32–33. doi:10.1111/jocd.15414
   PubMed Web of Science ®Google Scholar
• Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence. J Am Acad Dermatol. 2021;85(5):1274–1284. doi:10.1016/j.jaad.2021.07.054
   PubMed Web of Science ®Google Scholar
• Martora F, Battista T, Marasca C, Genco L, Fabbrocini G, Potestio L. Cutaneous reactions following COVID-19 vaccination: a review of the current literature. Clin Cosmet Investig Dermatol. 2022;15:2369–2382. doi:10.2147/CCID.S388245
   PubMed Web of Science ®Google Scholar
• van Dam CS, Lede I, Schaar J, Al-Dulaimy M, Rösken R, Smits M. Herpes zoster after COVID vaccination. Int J Infect Dis. 2021;111:169–171. doi:10.1016/j.ijid.2021.08.048
   PubMed Web of Science ®Google Scholar
• Akpandak I, Miller DC, Sun Y, Arnold BF, Kelly JD, Acharya NR. Assessment of herpes zoster risk among recipients of COVID-19 vaccine. JAMA Netw open. 2022;5(11):e2242240. doi:10.1001/jamanetworkopen.2022.42240
   PubMed Web of Science ®Google Scholar
• Eid E, Abdullah L, Kurban M, Abbas O. Herpes zoster emergence following mRNA COVID-19 vaccine. J Med Virol. 2021;93(9):5231–5232. doi:10.1002/jmv.27036
   PubMed Web of Science ®Google Scholar
• Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14(2). doi:10.3390/v14020192
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Florea A, Wu J, Qian L, et al. Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines. 2023;22(1):643–649. doi:10.1080/14760584.2023.2232451
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–1090. doi:10.1056/NEJMoa2110475
   PubMed Web of Science ®Google Scholar
• Monastirli A, Pasmatzi E, Badavanis G, Panagiotopoulou G, Apostolidou A, Tsambaos D. Herpes Zoster after mRNA COVID-19 vaccination: a case series. Skinmed. 2022;20(4):284–288.
   PubMedGoogle Scholar
• Psichogiou M, Samarkos M, Mikos N, Hatzakis A. Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines. 2021;9(6):572. doi:10.3390/vaccines9060572
   PubMed Web of Science ®Google Scholar
• Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330–1338. doi:10.1136/annrheumdis-2021-220647
   PubMed Web of Science ®Google Scholar
• Rodríguez-Jiménez P, Chicharro P, Cabrera LM, et al. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Rep. 2021;12:58–59. doi:10.1016/j.jdcr.2021.04.014
   PubMedGoogle Scholar
• Alpalhão M, Filipe P. Herpes Zoster following SARS-CoV-2 vaccination - A series of four cases. J Eur Acad Dermatol Venereol. 2021;35(11):e750–e752. doi:10.1111/jdv.17555
   PubMed Web of Science ®Google Scholar
• Chiu HH, Wei KC, Chen A, Wang WH. Herpes zoster following COVID-19 vaccine: a report of three cases. QJM. 2021;114(7):531–532. doi:10.1093/qjmed/hcab208
   PubMed Web of Science ®Google Scholar
• Jiang ZH, Wong LS, Lee CH, Hsu TJ, Yu YH. Disseminated and localised herpes zoster following Oxford-AstraZeneca COVID-19 vaccination. Indian J Dermatol Venereol Leprol. 2022;88(3):445. doi:10.25259/IJDVL_819_2021
   PubMed Web of Science ®Google Scholar
• Lazzaro DR, Ramachandran R, Cohen E, Galetta SL. Covid-19 vaccination and possible link to Herpes zoster. Am J Ophthalmol Case Rep. 2022;25:101359. doi:10.1016/j.ajoc.2022.101359
   PubMedGoogle Scholar
• Mohta A, Arora A, Srinivasa R, Mehta RD. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria being treated with cyclosporine-A report of 3 cases. J Cosmet Dermatol. 2021;20(11):3384–3386. doi:10.1111/jocd.14437
   PubMed Web of Science ®Google Scholar
• Vastarella M, Picone V, Martora F, Fabbrocini G. Herpes zoster after ChAdOx1 nCoV-19 vaccine: a case series. J Eur Acad Dermatol Venereol. 2021;35(12):e845–e846. doi:10.1111/jdv.17576
   PubMed Web of Science ®Google Scholar
• Birabaharan M, Kaelber DC, Karris MY. Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: a cohort study. J Am Acad Dermatol. 2022;87(3):649–651. doi:10.1016/j.jaad.2021.11.025
   PubMed Web of Science ®Google Scholar
• Özdemir AK, Kayhan S, Çakmak SK. Herpes zoster after inactivated SARS-CoV-2 vaccine in two healthy young adults. J Eur Acad Dermatol Venereol. 2021;35(12):e846–e847. doi:10.1111/jdv.17577
   PubMed Web of Science ®Google Scholar
• Palanivel JA. Herpes zoster after COVID-19 vaccination-Can the vaccine reactivate latent zoster virus? J Cosmet Dermatol. 2021;20(11):3376–3377. doi:10.1111/jocd.14470
   PubMed Web of Science ®Google Scholar
• Rehman O, Arya SK, Jha UP, Nayyar S, Goel I. Herpes zoster ophthalmicus after COVID-19 vaccination: chance occurrence or more? Cornea. 2022;41(2):254–256. doi:10.1097/ICO.0000000000002881
   PubMed Web of Science ®Google Scholar
• Toscani I, Troiani A, Citterio C, Rocca G, Cavanna L. Herpes zoster following COVID-19 vaccination in long-term breast cancer survivors. Cureus. 2021;13(10):e18418. doi:10.7759/cureus.18418
   PubMed Web of Science ®Google Scholar
• Aksu SB, Öztürk GZ. A rare case of shingles after COVID-19 vaccine: is it a possible adverse effect? Clin Exp Vaccine Res. 2021;10(2):198–201. doi:10.7774/cevr.2021.10.2.198
   PubMed Web of Science ®Google Scholar
• Ardalan M, Moslemi H, Shafiei S, Tabrizi R, Moselmi M. Herpes-like skin lesion after AstraZeneca vaccination for COVID-19: a case report. Clin Case Rep. 2021;9(10):e04883. doi:10.1002/ccr3.4883
   PubMed Web of Science ®Google Scholar
• Channa L, Torre K, Rothe M. Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination. JAAD Case Rep. 2021;15:60–61. doi:10.1016/j.jdcr.2021.05.042
   PubMedGoogle Scholar
• David E, Landriscina A. Herpes Zoster following COVID-19 vaccination. J Drugs Dermatol. 2021;20(8):898–900. doi:10.36849/JDD.6146
   PubMed Web of Science ®Google Scholar
• Tessas I, Kluger N. Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(10):e620–e622. doi:10.1111/jdv.17422
   PubMed Web of Science ®Google Scholar
• Tripathy DM, Kumar S, Saraswat N, Goel S, Ranjan E. Postherpetic granulomatous dermatitis and herpes zoster necroticans triggered by Covid-19 vaccination. Dermatol Ther. 2022;35(10):e15707. doi:10.1111/dth.15707
   PubMed Web of Science ®Google Scholar
• Akpandak I, Sechrist SJ, Miller DC, et al. Risk of herpes zoster ophthalmicus after COVID-19 vaccination in a large US healthcare claims database. Am J Ophthalmol. 2023. doi:10.1016/j.ajo.2023.07.004
   PubMed Web of Science ®Google Scholar
• Vallianou NG, Tsilingiris D, Karampela I, Liu J, Dalamaga M. Herpes zoster following COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster adult: a two-vaccine related event? Metab Open. 2022;13:100171. doi:10.1016/j.metop.2022.100171
   PubMedGoogle Scholar
• You IC, Ahn M, Cho NC. A case report of herpes zoster ophthalmicus and meningitis after COVID-19 vaccination. J Korean Med Sci. 2022;37(20):e165. doi:10.3346/jkms.2022.37.e165
   PubMed Web of Science ®Google Scholar
• Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022;186(1):142–152. doi:10.1111/bjd.20639
   PubMed Web of Science ®Google Scholar
• Fathy RA, McMahon DE, Lee C, et al. Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an International Dermatology Registry. J Eur Acad Dermatol Venereol. 2022;36(1):e6–e9. doi:10.1111/jdv.17646
   PubMed Web of Science ®Google Scholar
• Naoum C, Hartmann M. Herpes zoster reactivation after COVID-19 vaccination - A retrospective case series of 22 patients. Int J Dermatol. 2022;61(5):628–629. doi:10.1111/ijd.16116
   PubMed Web of Science ®Google Scholar
• Lee C, Cotter D, Basa J, Greenberg HL. 20 Post-COVID-19 vaccine-related shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social media. J Cosmet Dermatol. 2021;20(7):1960–1964. doi:10.1111/jocd.14210
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim YY, Heo HJ, Park JH, Cho HG, Kim G. Herpes zoster after COVID-19 vaccination, aspect of pain medicine: a retrospective, single-center study. Anesth pain Med. 2023;18(1):57–64. doi:10.17085/apm.22207
   Google Scholar
• McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46–55. doi:10.1016/j.jaad.2021.03.092
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280–2282. doi:10.1111/ced.15336
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. Clin Exp Dermatol. 2022;47(12):2310–2312. doi:10.1111/ced.15395
   PubMed Web of Science ®Google Scholar
• Martora F, Martora L, Fabbrocini G, Marasca C. A case of pemphigus vulgaris and hidradenitis suppurativa: may systemic steroids be considered in the standard management of hidradenitis suppurativa? Ski Appendage Disord. 2022;8(3):265–268. doi:10.1159/000521712
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Nappa P, Megna M. Impact of the COVID-19 pandemic on hospital admissions of patients with rare diseases: an experience of a Southern Italy referral center. Int J Dermatol. 2022;61(7):e237–e238. doi:10.1111/ijd.16236
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023:1–17. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023:1–16. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Martora F, Megna M, Battista T, et al. Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023;16:135–148. doi:10.2147/CCID.S391356
   PubMed Web of Science ®Google Scholar
• Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. Dermatol Ther. 2021;34(6):e15120. doi:10.1111/dth.15120
   PubMed Web of Science ®Google Scholar
• Patruno C, Potestio L, Napolitano M. Clinical phenotypes of adult atopic dermatitis and related therapies. Curr Opin Allergy Clin Immunol. 2022;22(4):242–249. doi:10.1097/ACI.0000000000000837
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Patruno C, Potestio L, Scalvenzi M, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. J Dermatolog Treat. 2022:1–6. doi:10.1080/09546634.2022.2102121
   PubMed Web of Science ®Google Scholar
• Villani A, Potestio L, Fabbrocini G, Scalvenzi M. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Adv Ther. 2022;39(3):1164–1178. doi:10.1007/s12325-022-02044-1
   PubMed Web of Science ®Google Scholar
• Ahmed B, Qadir MI, Ghafoor S. Malignant melanoma: skin cancer-diagnosis, prevention, and treatment. Crit Rev Eukaryot Gene Expr. 2020;30(4):291–297. doi:10.1615/CritRevEukaryotGeneExpr.2020028454
   PubMed Web of Science ®Google Scholar
• Villani A, Ocampo-Garza SS, Potestio L, et al. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Drug Saf. 2022;21(1):21–29. doi:10.1080/14740338.2022.1993819
   PubMed Web of Science ®Google Scholar
• Marasca C, Annunziata MC, Camela E, et al. Teledermatology and inflammatory skin conditions during COVID-19 era: new perspectives and applications. J Clin Med. 2022;11(6):1511. doi:10.3390/jcm11061511
   PubMed Web of Science ®Google Scholar
• Roizmann B, Desrosiers RC, Fleckenstein B, Lopez C, Minson AC, Studdert MJ. The family herpesviridae: an update. The Herpesvirus Study Group of the International Committee on Taxonomy of Viruses. Arch Virol. 1992;123(3–4):425–449. doi:10.1007/BF01317276
   PubMedGoogle Scholar
• Kukhanova MK, Korovina AN, Kochetkov SN. Human herpes simplex virus: life cycle and development of inhibitors. Biochemistry. 2014;79(13):1635–1652. doi:10.1134/S0006297914130124
   PubMed Web of Science ®Google Scholar
• Carneiro VC, de S, Pereira JG, de Paula VS. Family Herpesviridae and neuroinfections: current status and research in progress. Mem Inst Oswaldo Cruz. 2022;117:e220200. doi:10.1590/0074-02760220200
   PubMed Web of Science ®Google Scholar
• Brambilla L, Maronese CA, Tourlaki A, Veraldi S. Herpes zoster following COVID-19: a report of three cases. Eur J Dermatol. 2020;30(6):754–756. doi:10.1684/ejd.2020.3924
   PubMed Web of Science ®Google Scholar
• Shafiee A, Amini MJ, Arabzadeh Bahri R, et al. Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis. Eur J Med Res. 2023;28(1):278. doi:10.1186/s40001-023-01238-9
   PubMed Web of Science ®Google Scholar
• Stoeger T, Adler H. “Novel” triggers of herpesvirus reactivation and their potential health relevance. Front Microbiol. 2018;9:3207. doi:10.3389/fmicb.2018.03207
   PubMed Web of Science ®Google Scholar
• Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: the role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem Toxicol. 2022;164:113008. doi:10.1016/j.fct.2022.113008
   PubMed Web of Science ®Google Scholar
• Liu J, Wang J, Xu J, et al. Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines. Cell Discov. 2021;7(1):99. doi:10.1038/s41421-021-00329-3
   PubMed Web of Science ®Google Scholar
• Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202(5):637–650. doi:10.1084/jem.20050821
   PubMed Web of Science ®Google Scholar
• Desai HD, Sharma K, Shah A, et al. Can SARS-CoV-2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review. J Cosmet Dermatol. 2021;20(11):3350–3361. doi:10.1111/jocd.14521
   PubMed Web of Science ®Google Scholar
• Etaee F, Naguib T, Daveluy S. Herpes zoster dermatitis in a COVID-19 vaccinated healthy man after 1 dose of varicella vaccine. JAAD Case Rep. 2022;22:102–103. doi:10.1016/j.jdcr.2021.12.043
   PubMedGoogle Scholar
• Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med. 2023;12(9):3233. doi:10.3390/jcm12093233
   PubMed Web of Science ®Google Scholar
• Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab. J Cosmet Dermatol. 2023;22(3):1146–1148. doi:10.1111/jocd.15543
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Genco L, Martora F, Potestio L, Patruno C. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol. 2022;36(9):1497–1498. doi:10.1111/jdv.18137
   PubMed Web of Science ®Google Scholar
• Picone V, Martora F, Fabbrocini G, Marano L. “Covid arm”: abnormal side effect after Moderna COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15197. doi:10.1111/dth.15197
   PubMed Web of Science ®Google Scholar
• Picone V, Fabbrocini G, Martora L, Martora F. A case of new-onset lichen planus after COVID-19 vaccination. Dermatol Ther. 2022;12(3):801–805. doi:10.1007/s13555-022-00689-y
   Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;1–16. doi:10.1080/13543784.2023.2219387
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;1–3. doi:10.1080/14712598.2022.2113872
   Web of Science ®Google Scholar